Neurocognition After Radiotherapy in CNS- and Skull-base Tumors

Summary

The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning. All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.

Eligibility

Inclusion Criteria:

* Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation)

Exclusion Criteria:

* Patients with tumours with poor prognostic characteristics:

  * Incompletely resected IDH-wild-type glioma
  * Completely resected IDH-wild-type and MGMT-promotor unmethylated glioma
  * grade III meningioma
  * H3K27M+ midline glioma
* Patients with tumours requiring craniospinal irradiation (CSI)/whole ventricular irradiation (WVI)
* Hypofractionated/stereotactic radiation (fraction sizes \> 2 Gy per fraction)
* Inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient Dutch language proficiency
* Mental retardation documented before diagnosis
* Pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders)
* Relapse previously treated by chemo and/or radiation therapy
* Genetic syndrome (e.g. Down)
* Unable to perform MR imaging (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)

Conditions7

Browse More Trials